Trial reportAmerican journal of respiratory and critical care medicine2009
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.
Trial report in American journal of respiratory and critical care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 6 syntheses or guidelines pooled it, 247 citations in OpenAlex.
- Incidence and predictors of acute respiratory distress syndrome in sepsis: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Statins & risk ofThe Indian journal of medical research · 2019Pooled it
- Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials.Intensive care medicine · 2017Pooled it
- Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies.Critical care (London, England) · 2014Pooled it
- Clinical review: Statins and trauma--a systematic review.Critical care (London, England) · 2013Pooled it
- The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials.BMC medicine · 2013Pooled it
- Trial
- Simvastatin in Critically Ill Patients with Covid-19.The New England journal of medicine · 2023Trial
- Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials.Critical care (London, England) · 2023Trial
- Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial.Journal of medical virology · 2022Trial
- Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial.Critical care (London, England) · 2022Trial
- Bolus intravenous 0.9% saline leads to interstitial permeability pulmonary edema in healthy volunteers.European journal of applied physiology · 2021Trial
- Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study.Intensive care medicine · 2018Trial
- Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial.The Lancet. Respiratory medicine · 2018Trial
- Trial
- Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS.Thorax · 2017Trial
- Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial.The Lancet. Respiratory medicine · 2016Trial
- Trial
- Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human.BMC pharmacology & toxicology · 2014Trial
- Trial
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
rationaleSimvastatin inhibits inflammatory responses in vitro and in murine models of lung inflammation in vivo. As simvastatin modulates a number of the underlying processes described in acute lung injury (ALI), it may be a potential therapeutic option.
objectivesTo investigate in vivo if simvastatin modulates mechanisms important in the development of ALI in a model of acute lung inflammation induced by inhalation of lipopolysaccharide (LPS) in healthy human volunteers.
methodsThirty healthy subjects were enrolled in a double-blind, placebo-controlled study. Subjects were randomized to receive 40 mg or 80 mg of simvastatin or placebo (n = 10/group) for 4 days before inhalation of 50 microg LPS. Measurements were performed in bronchoalveolar lavage fluid (BALF) obtained at 6 hours and plasma obtained at 24 hours after LPS challenge. Nuclear translocation of nuclear factor-kappaB (NF-kappaB) was measured in monocyte-derived macrophages. MEASUREMENTS AND MAIN
resultsPretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). There was no significant difference between simvastatin 40 mg and 80 mg. BALF from subjects post-LPS inhalation induced a threefold up-regulation in nuclear NF-kappaB in monocyte-derived macrophages (P < 0.001); pretreatment with simvastatin reduced this by 35% (P < 0.001).
conclusionsSimvastatin has antiinflammatory effects in the pulmonary and systemic compartment in humans exposed to inhaled LPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.